Patient characteristics in ticlopidine hydrochloride-induced liver injury: Case-control study

Hepatology Research

Volumn 33, Issue 3, 2005, Pages 234-240

  Mizushima, Miyoko ^a   Iwata, Norikazu ^a   Fujimoto, Tetsuro Takahiro ^a   Ishikawa, Kiyomu ^b   Fujimura, Kingo ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cholestasis; Liver injury; Renal abnormalities; Ticlopidine hydrochloride

Indexed keywords

CYTOCHROME P450 1A; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ENZYME INHIBITOR; TICLOPIDINE; URSODEOXYCHOLIC ACID DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHOLESTASIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; DRUG ANTAGONISM; FEMALE; HUMAN; JAPAN; KIDNEY DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 29144532229     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2005.05.009     Document Type: Article

References (20)

1. M. Gent et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke Lancet 1 8649 1989 1215-1220
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86.
3. L. Nicola et al. Ticlopidine-induced cholestatic hepatitis successfully treated with corticosteroids: A case report Hepatol Res 28 2004 109-112
4. A. Conforti et al. Spontaneous reporting of drug-related hepatic reactions from two Italian regions (Lombardy and Veneto) Dig Liver Dis 32 8 2000 716-723
5. G. Danan C. Benichou Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries J Clin Epidemiol 46 11 1993 1323-1330
6. H. Takikawa et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting Hepatol Res 27 3 2003 192-195
7. M. Kojima et al. Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: A preliminary study Int J Urol 9 1 2002 42-46
8. T. Tomoda et al. Therapeutic effect of ursodeoxycholic acid on sulpyrine-induced intrahepatic cholestasis. A case report Nippon Shokakibyo Gakkai Zasshi 81 11 1984 2821-2825
9. D. McTavish et al. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders Drugs 40 2 1990 238-259
10. J.P. Desager Clinical pharmacokinetics of ticlopidine Clin Pharmacokinet 26 5 1994 347-355
11. W.M. Lee Drug-induced hepatotoxicity N Engl J Med 349 5 2003 474-485
12. H. Jaeschke et al. Mechanisms of hepatotoxicity Toxicol Sci 65 2 2002 166-176
13. H.J. Zimmerman et al. Ticrynafen-associated hepatic injury: Analysis of 340 cases Hepatology 4 2 1984 315-323
14. M.P. Lopez-Garcia et al. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: Inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid Biochemistry 33 1 1994 166-175
15. S.J.O. Veldhuyzen van Zanten C.W. McCormick Antinuclear antibody-positive ticlopidine-induced hepatitis Can J Gastroenterol 10 4 1996 231-232
16. M.H. Tsai et al. Ticlopidine-induced cholestatic hepatitis with anti-nuclear antibody in serum J Formos Med Assoc 99 11 2000 866-869
17. J.W. Ko et al. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: Potent effect on CYP2C19 and CYP2D6 Br J Clin Pharmacol 49 4 2000 343-351
18. T. Richter et al. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine J Pharmacol Exp Ther 308 1 2004 189-197
19. D.K. Dalvie T.N. O'Connell Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: Role of peroxidases, cytochromes p450, and monoamine oxidases Drug Metab Dispos 32 1 2004 49-57
20. Y. Maeda et al. Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin) in cancer patients Oncol Rep 12 3 2004 581-585